Cite
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.
MLA
Barth, Aline, et al. “Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.” Clinical Pharmacology in Drug Development, vol. 12, no. 1, Jan. 2023, pp. 38–56. EBSCOhost, https://doi.org/10.1002/cpdd.1192.
APA
Barth, A., Hossain, M., Perry, C. R., Gross, A. S., Ogura, H., Shabbir, S., Thomas, S., Dumont, E. F., Brimhall, D. B., Srinivasan, M., & Swift, B. (2023). Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants. Clinical Pharmacology in Drug Development, 12(1), 38–56. https://doi.org/10.1002/cpdd.1192
Chicago
Barth, Aline, Mohammad Hossain, Caroline R. Perry, Annette S. Gross, Hirofumi Ogura, Shaila Shabbir, Sebin Thomas, et al. 2023. “Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.” Clinical Pharmacology in Drug Development 12 (1): 38–56. doi:10.1002/cpdd.1192.